Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity

Recruiting Observational Study
Antibody Mediated Rejection After Kidney Transplantation
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
45 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Humoral rejection of kidney transplants is responsible for a large number of kidney graft losses in a context of increasing shortage. Although it has been established that it is largely mediated by the alloreactive B lymphocyte, anti-B therapies are only partially effective. The mechanisms behind the loss of tolerance are also poorly understood, and the triggers of rejection remain to be elucida…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult kidney transplant recipients admitted for biopsy or graft removal in the participating nephrology departments. * Patient participation agreement and signed consent form * Affiliation to a health insurance system Exclusion Criteria: * Confounding factor of renal inflamm…
Contacts

Yanis TAMZALI, MD, MsC

681402564

yanis.tamzali@aphp.fr

CONTACT